Webinar Abstract
DNA methylation is a common epigenetic modification that can alter gene expression. Aberrant DNA methylation is implicated in several disease processes, including cancer and degenerative diseases.
As DNA methylation is a genomic phenomena, accurate assessment of the DNA methylation landscape requires genome-scale tools. For human samples, investigators leverage both sequencing (Bisulphite sequencing) and array-based methodologies (Illumina 450K, EPIC arrays).
However, genomic-scale profiling of model organisms, including mice, has traditionally been limited to sequencing-based methods owing to the lack of cost-effective array based solutions. Illumina has recently developed a DNA methylation array specific to the murine samples, capturing DNA methylation information for >250,000 CpG sites.
In this webinar, Dr Fennell will discuss his impressions of the technology and present the results of a comparative analysis between the Illumina Mouse Methylation Array and Reduced Representation Bisulphite Sequencing in two models of colorectal cancer.
The key things you will learn include:
Dr Lochlan Fennell Dr Fennell is a computational biologist with an interest in cancer epigenetics at the interface of aging. He completed his PhD at the University of Queensland, where he evaluated the role of DNA methylation and aging in determining the risk of spontaneously progression colonic adenomas. He has published extensively in leading Journals including Gut, Cellular and Molecular Gastroenterology and Hepatology, and Clinical Epigenetics. Dr Fennell is currently a postdoctoral researcher at QIMR Berghofer Medical Research Institute in Brisbane, Australia, where he continues to research the role of age in shaping the epigenome and modifying cancer risk. |
Need help analyzing methylation array data? Watch our new SeSAMe video tutorials for methylation data analysis. Watch Now!